Audentes Therapeutics, a California-based startup specializing in gene treatments for very rare diseases, secured $30 million in a Series A funding round from 5AM Ventures, OrbiMed Advisors and Versant Ventures. The firm plans to use the proceeds to support development of treatments for rare diseases such as X-linked myotubular myopathy and Pompe disease.

Full Story:

Related Summaries